Kate wanted to die. She remembers the moment the psychiatrist said “the antidepressant isn’t going to work right away. Can you promise to be here next week and not kill yourself?” “I told her no,” Kate says.
Dennis Hartman, a 47-year-old former business executive for an Illinois gaming company, described the diagnosis he had been given as “major depression disorder with severity of the extreme, social phobia and generalized anxiety disorder,” something he had lived with for more than 30 years.
New types of drugs for schizophrenia, depression and other psychiatric disorders are few and far between—and a number of companies have scaled back or dropped development of this class of pharmaceuticals.
Ketamine, a Darling of the Club Scene, Inspires Development of Next-Generation Antidepressants, Part 3
Recent experimental research showing that the anesthetic and club drug ketamine can relieve depression quickly has intrigued a number of major pharmaceutical companies.